Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Takeda Pharmaceutical Co Ltd | 10%+ Owner | $4.93M | Oct 12, 2021 | ||
Foresite Capital Management V, LLC | 10%+ Owner | $4.23M | Jul 17, 2023 | ||
Omega Fund VI, L.P. | Former 10% owner | $2.17M | Oct 12, 2021 | ||
William Shakespeare | President of Research and Development | $2.02M | Nov 6, 2023 | ||
Rock Springs Capital Management LP | 10%+ Owner | $1.83M | Oct 12, 2021 | ||
Timothy P. Clackson | President and CEO, Director | $139K | Mar 1, 2023 | ||
David Kerstein | Chief Medical Officer | $53.4K | Mar 1, 2023 | ||
Victor Rivera | Chief Scientific Officer | $49.6K | Mar 1, 2023 | ||
Donald J. Hayden Jr | Director | $0 | Feb 14, 2024 | ||
Kathy Yi | Director | $0 | Feb 14, 2024 | ||
Carl L. Gordon | Director, 10%+ Owner | $0 | Feb 14, 2024 | ||
Orbimed Advisors Llc | Director, 10%+ Owner | $0 | Feb 14, 2024 | ||
Iain D. Dukes | Director | $0 | Feb 14, 2024 | ||
Steven H. Stein | Director | $0 | Feb 14, 2024 | ||
D. Dahms | President and CFO | $0 | Feb 14, 2024 | ||
David Dalgarno | Chief Technical Officer | Feb 18, 2022 | |||
Michael E. Rome | Director | Oct 6, 2021 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|